Archives
-
DOTMA and mRNA Delivery: Reading the Evidence
2026-10-09
Explore how DOTMA-based lipoplexes fit within the evolving mRNA delivery landscape. This evidence-focused analysis distinguishes DOTMA from the CAF04 platform studied in a 2026 lymphoma model and explains what the findings do—and do not—establish for translational research.
-
Bufalin, CENPA, and Glycolysis in HCC
2026-10-09
A 2026 pre-proof study links Bufalin to CENPA-associated glycolysis, PI3K/AKT signaling, and hepatocellular carcinoma cell migration through integrated bioinformatics, cell-based assays, docking, and preliminary xenograft evidence. The findings support a mechanistic research hypothesis rather than clinical efficacy, with important limits around causality, model scope, and the predictive nature of docking.
-
Nirmatrelvir Evidence: Five Questions Answered
2026-10-08
A source-grounded overview of Nirmatrelvir and PF-07321332, explaining the 3CL protease principle, the difference between computational and clinical evidence, applicable populations, and major limitations in COVID-19 and antiviral therapeutics research.
-
LY2886721 and BACE1: Evidence in Alzheimer’s Research
2026-10-08
LY2886721 is a research compound used to study BACE1-dependent amyloid precursor protein processing. This overview compares supplier-reported biochemical and animal findings with peer-reviewed evidence from neuronal cultures, emphasizing what amyloid beta reduction can—and cannot—establish about synaptic function, Alzheimer’s disease biology, and translational relevance.
-
Dense RNA Motifs Improve In Vivo Prime Editing
2026-10-07
The reference study reports that densely modified RNA motifs in prime editing guide RNAs can substantially improve RNA-delivered prime editing in mouse liver and increase the activity of other split RNA-guided editing systems. Its findings support a transient, non-viral delivery strategy, while remaining limited by the preclinical model, delivery context, and need for further validation across tissues and species.
-
4-PBA and ER Stress in Liver Cancer Research
2026-10-07
This overview examines 4-Phenylbutyric acid (4-PBA) as a research tool for interpreting endoplasmic reticulum stress, autophagy, and cell death. It evaluates findings from a 2026 liver cancer study, explains what the evidence supports, and outlines important limitations around pathway specificity, model relevance, and translation.
-
How Cell Divisions Refine Drosophila Boundaries
2026-10-06
Castle et al. show that cell divisions have a dual mechanical role at the mesectoderm–ectoderm boundary in the Drosophila embryo: they can challenge boundary integrity while also improving boundary linearity. By combining mathematical modelling, in vivo perturbation, laser ablation, and cell tracking, the study identifies division-driven tissue fluidity as a previously unreported mechanism of boundary refinement.
-
Aurora A in High-Risk Retinoblastoma
2026-10-06
A 2024 American Journal of Pathology study links elevated Aurora kinase A (AURKA) expression with histopathologic features of high-risk retinoblastoma and evaluates the kinase as more than a prognostic marker. By integrating patient specimens with genetic, pharmacologic, patient-derived, xenograft, and enucleated-tissue models, the study provides a disease-specific preclinical rationale for investigating AURKA-directed therapies while leaving clinical efficacy unresolved.
-
OLIG2 mRNA Drives Rapid Oligodendrocyte Differentiation
2026-10-05
Xu and colleagues developed a non-integrating synthetic modified messenger RNA strategy that uses OLIG2 S147A to direct human induced pluripotent stem cells toward oligodendrocyte progenitor cells. The reported system generated more than 70% NG2-positive progenitors within a six-day induction framework, with subsequent maturation into functional oligodendrocytes and evidence of remyelination in vivo.
-
15-PGDH Inhibition and Muscle Repair During Weight Loss
2026-10-05
A 2026 PNAS study reports that 15-PGDH inhibition improved muscle stem cell activity, regenerated myofiber growth, and force recovery in obese mice receiving semaglutide after muscle injury. The combination preserved semaglutide-associated weight loss while improving postinjury muscle quality, although the evidence remains preclinical and specific to the study model.
-
DOTMA in mRNA Delivery: Evidence and Limits
2026-10-04
Explore DOTMA mRNA delivery through a formulation-level analysis of cationic liposomes, CD8+ T-cell responses, and cancer-vaccine evidence. The article separates findings from a 2026 murine study from claims that can be made about standalone DOTMA.
-
DMG-PEG2000-NH2: Evidence, Context, and Limits
2026-10-03
DMG-PEG2000-NH2 is a primary-amine-terminated PEG lipid linker discussed by its supplier for conjugation and lipid-based delivery research. The supplied tuberculosis study provides evidence for sulfaphenazole-derived sulfonamide activity, but it does not evaluate DMG-PEG2000-NH2, liposomes, LNPs, or siRNA delivery. This overview separates those evidence streams and defines their applicability boundaries.
-
SW033291: 15-PGDH Inhibitor Evidence
2026-10-02
SW033291 is a potent 15-PGDH inhibitor that raises prostaglandin E2 in biochemical and cellular assays. Its reported effects on hematopoiesis and tissue repair make it a useful preclinical tool for pathway-focused regeneration research.
-
Affordable GRO-seq for Nascent RNA Profiling in Wheat
2026-10-01
This protocol study introduces an rRNA depletion step between nuclear RNA isolation and nascent RNA immunoprecipitation, making GRO-seq more efficient for allohexaploid bread wheat. The approach increased the proportion of valid sequencing data by 20-fold in the reported application and provides a practical framework for studying enhancer transcription in large, complex genomes.
-
Two-Component Liposomes for mRNA Cancer Vaccines
2026-10-01
A 2026 study developed a stable two-component cationic liposome system that can be mixed with mRNA shortly before administration, avoiding some manufacturing complexity associated with conventional four-lipid nanoparticles. In a murine lymphoma model, optimized CAF04:mRNA formulations generated functional CD8+ T-cell responses, delayed tumor growth, and improved survival, supporting further investigation of adaptable mRNA cancer-vaccine platforms.